Healthcare · Pharmaceuticals & Biotechnology
QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Bearish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Lincoln Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is engaged in the manufacturing, marketing and distribution of pharmaceutical products.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #88 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 6 Jun 2024 | Munjal Mahendrabhai Patel | Promoter group | Buy | 0 | ₹0 |
| 3 Jun 2024 | Munjal Mahendrabhai Patel | Promoter group | Buy | 0 | ₹0 |
| 3 Jun 2024 | Munjal Mahendrabhai Patel | Promoter group | Buy | 0 | ₹0 |
| 28 Feb 2024 | Renukaben Maheshbhai Patel | Promoter group | Sell | 0 | ₹0 |
| 28 Feb 2024 | Patel Nishitkumar Maheshbhai | Promoter group | Sell | 0 | ₹0 |
| 28 Feb 2024 | Patel Nishitkumar Maheshbhai | Promoter group | Sell | 0 | ₹0 |
| 24 Feb 2024 | Renukaben Maheshbhai Patel | Promoter group | Sell | 0 | ₹0 |
| 24 Feb 2024 | Patel Nishitkumar Maheshbhai | Promoter group | Sell | 0 | ₹0 |
| 23 Feb 2024 | Anand Arvindbhai Patel | Promoter group | Buy | 0 | ₹0 |
| 22 Feb 2024 | Renukaben Maheshbhai Patel | Promoter group | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 29 Apr 2026 | QE SECURITIES LLP | Bulk | Buy | 109,936 | 701.4600 | NSE |
| 29 Apr 2026 | QE SECURITIES LLP | Bulk | Sell | 106,989 | 709.2800 | NSE |
| 29 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 208,466 | 707.9300 | NSE |
| 29 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Buy | 208,466 | 707.5100 | NSE |
| 12 Feb 2026 | GREENX WEALTH MULTIHORIZONS OPPORTUNITY FUND | Bulk | Buy | 165,255 | 603.0700 | NSE |
| 7 Aug 2025 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 275,585 | 600.3900 | NSE |
| 7 Aug 2025 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Buy | 275,585 | 599.4900 | NSE |
| 7 Aug 2025 | MUSIGMA SECURITIES | Bulk | Sell | 160,300 | 606.0400 | NSE |
| 7 Aug 2025 | MUSIGMA SECURITIES | Bulk | Buy | 160,300 | 604.9700 | NSE |
| 7 Aug 2025 | IRAGE BROKING SERVICES LLP | Bulk | Buy | 137,847 | 600.7400 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 11 Sep 2026 | Dividend - Rs 1.80 Per Share | 1.8000 | 11 Sep 2026 |
| 12 Sep 2025 | Dividend - Rs 1.80 Per Share | 1.8000 | 12 Sep 2025 |
| 13 Sep 2024 | Dividend - Rs 1.80 Per Share | 1.8000 | — |
| 15 Sep 2023 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 1.5000 | — |
| 15 Sep 2022 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 1.5000 | — |
| 16 Sep 2021 | Dividend - Rs 1.50 Per Share | 1.5000 | — |
| 5 Mar 2020 | Interim Dividend - Rs 1.5 Per Share | 1.5000 | 6 Mar 2020 |
| 19 Sep 2019 | Dividend - Rs 1.5 Per Share | 1.5000 | — |
| 19 Sep 2018 | Dividend Rs 1.50 Per Share | 1.5000 | — |
| 21 Sep 2017 | Annual General Meeting/Dividend - Rs 1.20 Per Share | 1.2000 | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 17 Sep 2020 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 13 Aug 2026 | Financial Results | Yes |
| 28 May 2026 | Financial Results/Dividend | Yes |
| 12 Feb 2026 | Financial Results | Yes |
| 13 Nov 2025 | Financial Results | Yes |
| 7 Aug 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 3 Oct 2026 | Shareholders meeting | Lincoln Pharmaceuticals Limited has informed the Exchange a copy of Voting Results of Annual General Meeting held on September 30, 2026. |
| 3 Oct 2026 | AGM/EGM | Lincoln Pharmaceuticals Ltd - 531633 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 30 Sep 2026 | AGM/EGM | Lincoln Pharmaceuticals Ltd - 531633 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 30 Sep 2026 | Shareholders meeting | Lincoln Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026 |
| 24 Sep 2026 | Change in Management | Lincoln Pharmaceuticals Limited has informed the Exchange about change in Management |
| 24 Sep 2026 | Change in Management | Lincoln Pharmaceuticals Limited has informed the Exchange about change in Management |
| 23 Sep 2026 | Trading Window | Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 7 Sep 2026 | Copy of Newspaper Publication | Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for Notice of 32nd Annual General Meeting. |
| 5 Sep 2026 | AGM/EGM | Lincoln Pharmaceuticals Ltd - 531633 - Notice Of 32Nd Annual General Meeting Of The Company. |
| 5 Sep 2026 | Company Update | Lincoln Pharmaceuticals Ltd - 531633 - Update Regarding Dispatch Of Physical Communication To Shareholders To Access Annual Report Of The Company. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
